PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus

Diagnostic Molecular Pathology

Volumn 12, Issue 2, 2003, Pages 71-78

  Ricci, Romeo ^a   Komminoth, Paul ^a,d   Bannwart, Fridolin ^b   Torhorst, Joachim ^c   Wight, Edward ^a   Heitz, Philipp U ^a   Caduff, Rosmarie F ^a,e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Kantonsspital Baden   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Ovary; PTEN; Synchronous endometrioid carcinoma; Uterus

Indexed keywords

MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CHROMOSOME 10Q; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; FEMALE; GENE DELETION; GENE INSERTION; HETEROZYGOSITY LOSS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; MICROSATELLITE MARKER; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; STANDARD; UTERUS CARCINOMA;

AGED; CARCINOMA, ENDOMETRIOID; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PHOSPHORIC MONOESTER HYDROLASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0038779338     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200306000-00002     Document Type: Article

References (47)

1. Scully RE. Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament. Atlas of Tumor Pathology (AFIP, Atlas of Tumor Pathology No. 23). Washington, D.C., Am. Registry of Pathology, 1999:125-6.
2. Jambhekar NA, Sampat MB. Simultaneous endometrioid carcinoma of the uterine corpus and ovary: a clinicopathologic study of 15 cases. J Surg Oncol 1988;37:20-3.
3. Pearl ML, Johnston CM, Frank TS, et al. Synchronous dual primary ovarian and endometrial carcinomas. Int J Gynaecol Obstet 1993;43:305-12.
4. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas - a prospective clinocipathologic of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001;83:355-62.
5. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
6. Marsh DJ, Dahia PL, Zheng Z, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997;16:333-4.
7. Kwon CH, Zhu X, Zhang J, et al. PTEN regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 2001; 29:404-11.
8. Backman SA, Stambolic V, Suzuki A, et al. Deletion of PTEN in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 2001;29:396-403.
9. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999;96:4240-5.
10. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
11. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
12. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 1997;57:4183-6.
13. Di Cristofano A, De Acetis M, Koff A, et al. PTEN and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-4.
14. Feilotter HE, Nagai MA, Boag AH, et al. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998; 16:1743-8.
15. Yao YJ, Ping XL, Zhang H, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999;18:3181-5.
16. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998;16:3215-8.
17. Guldberg P, thor Straten P, Birck A, et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997;57:3660-3.
18. Rhei E, Kang L, Bogomolniy F, et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res 1997;57:3657-9.
19. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999;155:1253-60.
20. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecologic malignancies. Cancer Res 1997;57:3935-40.
21. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-4.
22. Risinger JI, Hayes AK, Berchuck A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-8.
23. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-7.
24. Simpkins SB, Peiffer-Schneider S, Mutch DG, et al. PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 1998;71:391-5.
25. Sun H, Enomoto T, Fujita M, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol 2001;115:32-8.
26. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.
27. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998; 58:3254-8.
28. Sun H, Enomoto T, Shroyer KR, et al. Clonal analysis and mutations in the PTEN and in K-ras genes in endometrial hyperplasias. Diagn Mol Pathol 2002;11:204-11.
29. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998;58:2095-7.
30. Saito M, Okamoto A, Kohno T, et al. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000; 85:160-5.
31. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clearq cell carcinoma of the ovary. Cancer Res 2000;60:7052-6.
32. Lin WM, Forgacs E, Warshal DP, et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 1998;4:2577-83.
33. Stambolic V, Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000;60:3605-11.
34. Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999;285:2122-5.
35. Wang H, Douglas, W, Lia M, et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in PTEN heterozygous mice. Am J Pathol 2002;160:1481-6.
36. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-90.
37. Sobin LH, Wittekind Ch, eds. TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss, 2002.
38. Wittekind Ch, Henson DE, Hutter RVP, et al, eds. TNM Supplement (ed 2). New York, NY: Wiley-Liss, 2001.
39. Perren A, Roth J, Muletta-Feurer S, et al. Clonal analysis of sporadic pancreatic endocrine tumors. J Pathol 1998;186:363-71.
40. Komminoth P, Muletta-Feurer A, Saremaslani P, et al. Molecular diagnosis of multiple endocrine neoplasia (MEN) in paraffin-embedded specimens. Endocr Pathol 1995;79:267-78.
41. Kurose K, Bando K, Fukino K, et al. Somatic mutations of the PTEN/MMAC1 gene in fifteen Japanese endometrial cancers: evidence for inactivation of both alleles. Jpn J Cancer Res 1998;89:842-8.
42. Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 1997;94:9052-7.
43. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 1998;95:13513-8.
44. Caduff RF, Svoboda-Newman SM, Bartos RE, et al. Comparative analysis of histologic homologues of endometrial and ovarian carcinomas. Am J Surg Pathol 1998;22:319-26.
45. Moreno-Bueno G, Gamallo C, Perez-Gallego L et al. Beta -Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001;10:116-22.
46. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of betacatenin deregulation in ovarian endometrioid andeocarcinomas. Cancer Res 2001;61:8247-55.
47. Schlosshauer PW, Pirog EC, Levine RL, et al. Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 2000;13:1066-71.